MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Cash and cashequivalents$3,240K (0.25%↑ Y/Y)Accounts receivable$1,000K (79.86%↑ Y/Y)Prepaid expenses$384K (-8.79%↓ Y/Y)Other current assets$11K (-31.25%↓ Y/Y)Other investment$5,350K (0.00%↑ Y/Y)Total current assets$4,635K (9.70%↑ Y/Y)Total assets$9,985K (4.28%↑ Y/Y)Total liabilities andstockholders' equity$9,985K (4.28%↑ Y/Y)Total stockholders'equity$9,085K (2.66%↑ Y/Y)Total currentliabilities$900K (24.14%↑ Y/Y)Accumulated deficit-$271,020K (-1.32%↓ Y/Y)Paid-in capital$280,105K (1.36%↑ Y/Y)Accounts payable$508K (30.26%↑ Y/Y)Accrued research anddevelopment costs$198K (280.77%↑ Y/Y)Accrued expenses andother current...$194K (-31.45%↓ Y/Y)
Balance Sheet
source: myfinsight.com

Cyclerion Therapeutics, Inc. (CYCN)

Cyclerion Therapeutics, Inc. (CYCN)